Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
The new sharewise is here Clearer, faster, with a light and a dark view — and everything you already know. Try it now
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Why Shares of UroGen Pharma Jumped Friday

TheMotleyFool 
0 0 28.07.23
Why Shares of UroGen Pharma Jumped FridayPhoto, wide shot, wide-angle lens, Mental health care service, Midday, harsh overhead sunlight, directional sunlightt, photo by Art Wolfe: https://img.midjourneyapi.xyz/temp/7ce3b930-5e2a-4215-b686-0ad0eb0b922a.png
 

Shares of UroGen Pharma (NASDAQ: URGN) were up more than 25% as of 1:20 p.m. ET on Friday. The biotech company announced positive phase 3 trial news for a bladder cancer therapy. The stock is up more than 152% this year.

UroGen focuses on urothelial and specialty cancers. On Thursday, the company announced positive top-line data from two phase 3 trials for UGN-102 (mitomycin), an intravesical (within the bladder) solution to treat patients with low-grade, intermediate-risk non-muscle-invasive bladder cancer (LG-IR-NMIBC).

Both trials met their primary endpoints. In the first, UGN-102 showed a 64.8% complete response rate at three months in patients, compared to a 63.6% complete response rate with patients who only received a transurethral resection of a bladder tumor (TURBT).

Continue reading


Source Fool.com

Like: 0
URGN
Share

Comments

Not a member yet? Sign up for free!